Literature DB >> 25785782

SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability.

Weijing Kong1, Yujia Zhang, Yang Gao, Xiaoyan Liu, Kai Gao, Han Xie, Jingmin Wang, Ye Wu, Yuehua Zhang, Xiru Wu, Yuwu Jiang.   

Abstract

OBJECTIVE: Mutations in SCN8A, a voltage-gated sodium-channel type VIII alpha subunit gene, have recently been recognized as one of the pathogenic mechanisms leading to epilepsy and intellectual/developmental disabilities (IDDs). The aim of this study was to detect SCN8A mutations in Chinese patients with epilepsy of unknown etiology and ID/DD.
METHODS: We used targeted next-generation sequencing to identify SCN8A mutations in Chinese patients with epilepsy of unknown etiology and IDDs. A filter process was performed to prioritize rare variants of potential functional significance. Sanger sequencing confirmed the variants and determined the parental origin. We followed all patients with SCN8A mutations in our cohort and analyzed their clinical data.
RESULTS: Five de novo SCN8A mutations were identified, including four novel mutations (p.Ala890Thr, p.Leu407Phe, p.Arg850Gln, and p.Ser1596Cys) and one reported (p.Arg1617Gln). Polyphen2 and SIFT software predicted that all five mutations probably damaged Nav1.6 protein function; Mutation Taster indicated that all mutations were disease-causing. Three of these five patients were controlled well by sodium channel blockers (SCBs). Two of these three patients remained seizure free for 6 and 1.5 months, respectively. One patient had sudden unexpected death in epilepsy (SUDEP) at the age of 1 year and 4 months. SIGNIFICANCE: Five SCN8A mutations were first reported in Chinese patients with epilepsy and ID/DD, expanding the phenotype and mutation spectrum of SCN8A mutations. Although three of these patients were controlled well by SCBs in our study, the effectiveness of SCBs should be validated in more patients with epilepsy caused by SCN8A mutations in the future. One of our five patients had sudden unexpected death in epilepsy SUDEP, suggesting that we should pay more attention to SUDEP in epileptic patients with SCN8A mutations. Wiley Periodicals, Inc.
© 2015 International League Against Epilepsy.

Entities:  

Keywords:  Epilepsy; Intellectual disability; SCN8A; Sodium channel blocker

Mesh:

Substances:

Year:  2015        PMID: 25785782     DOI: 10.1111/epi.12925

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

1.  Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers.

Authors:  Rikke S Møller; Katrine M Johannesen
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Clinical characteristics of two cohorts of infantile spasms: response to pyridoxine or topiramate monotherapy.

Authors:  Jiao Xue; Ping Qian; Hui Li; Ye Wu; Hui Xiong; Yue-Hua Zhang; Zhi-Xian Yang
Journal:  World J Pediatr       Date:  2018-04-26       Impact factor: 2.764

3.  Neuronal hyperexcitability in a mouse model of SCN8A epileptic encephalopathy.

Authors:  Luis F Lopez-Santiago; Yukun Yuan; Jacy L Wagnon; Jacob M Hull; Chad R Frasier; Heather A O'Malley; Miriam H Meisler; Lori L Isom
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

4.  SCN8A encephalopathy: Research progress and prospects.

Authors:  Miriam H Meisler; Guy Helman; Michael F Hammer; Brandy E Fureman; William D Gaillard; Alan L Goldin; Shinichi Hirose; Atsushi Ishii; Barbara L Kroner; Christoph Lossin; Heather C Mefford; Jack M Parent; Manoj Patel; John Schreiber; Randall Stewart; Vicky Whittemore; Karen Wilcox; Jacy L Wagnon; Phillip L Pearl; Adeline Vanderver; Ingrid E Scheffer
Journal:  Epilepsia       Date:  2016-06-08       Impact factor: 5.864

5.  Severe infantile onset developmental and epileptic encephalopathy caused by mutations in autophagy gene WDR45.

Authors:  Gemma L Carvill; Aijie Liu; Simone Mandelstam; Amy Schneider; Amy Lacroix; Matthew Zemel; Jacinta M McMahon; Luis Bello-Espinosa; Mark Mackay; Geoffrey Wallace; Michaela Waak; Jing Zhang; Xiaoling Yang; Stephen Malone; Yue-Hua Zhang; Heather C Mefford; Ingrid E Scheffer
Journal:  Epilepsia       Date:  2017-11-24       Impact factor: 5.864

6.  Cardiac arrhythmia in a mouse model of sodium channel SCN8A epileptic encephalopathy.

Authors:  Chad R Frasier; Jacy L Wagnon; Yangyang Oliver Bao; Luke G McVeigh; Luis F Lopez-Santiago; Miriam H Meisler; Lori L Isom
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-26       Impact factor: 11.205

7.  SCN8A epileptic encephalopathy mutations display a gain-of-function phenotype and divergent sensitivity to antiepileptic drugs.

Authors:  Qian-Bei Guo; Li Zhan; Hai-Yan Xu; Zhao-Bing Gao; Yue-Ming Zheng
Journal:  Acta Pharmacol Sin       Date:  2022-07-27       Impact factor: 7.169

8.  Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol.

Authors:  Reesha R Patel; Cindy Barbosa; Tatiana Brustovetsky; Nickolay Brustovetsky; Theodore R Cummins
Journal:  Brain       Date:  2016-06-05       Impact factor: 13.501

9.  Heterogeneous clinical and functional features of GRIN2D-related developmental and epileptic encephalopathy.

Authors:  Wenshu XiangWei; Varun Kannan; Yuchen Xu; Gabrielle J Kosobucki; Anthony J Schulien; Hirofumi Kusumoto; Christelle Moufawad El Achkar; Subhrajit Bhattacharya; Gaetan Lesca; Sylvie Nguyen; Katherine L Helbig; Jean-Marie Cuisset; Christina Dühring Fenger; Dragan Marjanovic; Elisabeth Schuler; Ye Wu; Xinhua Bao; Yuehua Zhang; Nina Dirkx; An-Sofie Schoonjans; Steffen Syrbe; Scott J Myers; Annapurna Poduri; Elias Aizenman; Stephen F Traynelis; Johannes R Lemke; Hongjie Yuan; Yuwu Jiang
Journal:  Brain       Date:  2019-10-01       Impact factor: 13.501

10.  Aberrant Sodium Channel Currents and Hyperexcitability of Medial Entorhinal Cortex Neurons in a Mouse Model of SCN8A Encephalopathy.

Authors:  Matteo Ottolini; Bryan S Barker; Ronald P Gaykema; Miriam H Meisler; Manoj K Patel
Journal:  J Neurosci       Date:  2017-07-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.